Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Melanie Joy to Treatment Outcome

This is a "connection" page, showing publications Melanie Joy has written about Treatment Outcome.

 
Connection Strength
 
 
 
0.269
 
  1. Jang SY, Dooley MA, Joy MS. Impact of severe hypothyroidism on cyclophosphamide disposition and routes of metabolism and transport in a patient with treatment-resistant lupus nephritis. Ann Pharmacother. 2013 Jul-Aug; 47(7-8):e35.
    View in: PubMed
    Score: 0.048
  2. Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010 Jan; 55(1):50-60.
    View in: PubMed
    Score: 0.038
  3. Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol. 2009 Jan; 4(1):39-47.
    View in: PubMed
    Score: 0.035
  4. Joy MS, Kshirsagar A, Candiani C, Brooks T, Hudson JQ. Lanthanum carbonate. Ann Pharmacother. 2006 Feb; 40(2):234-40.
    View in: PubMed
    Score: 0.029
  5. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant. 2005 Dec; 20(12):2725-32.
    View in: PubMed
    Score: 0.028
  6. Finn WF, Joy MS. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin. 2005 May; 21(5):657-64.
    View in: PubMed
    Score: 0.028
  7. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003 Jul; 42(1):96-107.
    View in: PubMed
    Score: 0.024
  8. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother. 1998 Mar; 32(3):362-75.
    View in: PubMed
    Score: 0.017
  9. Fink JC, Joy MS, St Peter WL, Wahba IM. Finding a common language for patient safety in CKD. Clin J Am Soc Nephrol. 2012 Apr; 7(4):689-95.
    View in: PubMed
    Score: 0.011
  10. Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, Savin V, Somers M, Pinsk M, Greene T. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol. 2011 Feb 10; 12:8.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)